POLD1 and nonpapillary renal cell carcinoma: In view of the diversity in infiltrating levels and the status of the immune cells between the POLD1high and POLD1low groups, ccRCC patients with POLD1 overexpression may not obtain benefits from more precise immunotherapy strategies in clinics.